|
Match
|
Document |
Document Title |
|
|
US20110047633 |
Control of Exocrine Pancreatic Function Using Bone Morphogenetic Proteins
Methods are described for controlling exocrine pancreatic function, for reducing the level of amylase in the blood, and for treating pancreatitis in an individual comprising administering to the...
|
|
|
US20110047631 |
HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER
The invention provides non-human transgenic animals as models of neurodegenerative brain pathology, including, but not limited to, Alzheimer's disease (AD), and cancer. The non-human transgenic...
|
|
|
US20120122144 |
METHODS EMPLOYING INSECT MODELS FOR DETERMINING INTESTINAL ABSORPTION OF CHEMICAL COMPOUNDS
There is provided insect screening models to determine gastrointestinal absorption of different chemical compounds in vertebrates, and in particular humans, in order to improve the compound...
|
|
|
US20110088103 |
ALLERGIC DISEASE MODEL ANIMALS
The object of the present invention is to provide a mouse model for allergic diseases such as atopic dermatitis, and a dermatitis mouse model with impaired skin-barrier function. The present...
|
|
|
US20110030070 |
DIAGNOSIS AND TREATMENT OF AUTISM USING CD38
The invention relates to a method for screening a pharmaceutical for treating or preventing a neurodevelopmental disorder or a psychiatric disorder accompanied by an abnormality of oxytocin system...
|
|
|
US20110263691 |
METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF
Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their...
|
|
|
US20110289605 |
Animal Model for Osteoarthritis and Intervertebral Disc Disease
Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated...
|
|
|
US20110082093 |
Methods and compositions for treating trinucleotide repeat disorders
Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
|
|
|
US20110214189 |
G PROTEIN COUPLED RECEPTORS AND USES THEREOF
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are...
|
|
|
US20110021605 |
MEANS AND METHODS FOR THE SPECIFIC INHIBITION OF GENES IN CELLS AND TISSUE OF THE CNS AND/OR EYE
Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye, wherein a composition comprising one or more doubled stranded...
|
|
|
US20110033442 |
TARGETS, INCLUDING YAP1, FOR ANTIFUNGAL DRUG DISCOVERY AND THERAPY
The present invention is based on the discovery of a two organism model system that can be used to identify virulence factors. The system is also useful in the process of drug delivery. More...
|
|
|
US20120060230 |
METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS
Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
|
|
|
US20110200982 |
GENETICALLY MODIFIED MICE AND ENGRAFTMENT
A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A...
|
|
|
US20110296540 |
ASSAY FOR SCREENING ANTIDEPRESSANTS
This invention provides a method for identifying a small molecule as an antidepressant, a method for identifying a small molecule as an anxiolytic, and a method for identifying a small molecule as...
|
|
|
US20110110902 |
MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING HEART DISEASE
The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting,...
|
|
|
US20100299768 |
Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease
Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which...
|
|
|
US20120079612 |
Dry eye animal model
A first embodiment is a dry eyed animal model method by peri or post-menopausal estrogen-treated rats have decreased tear production wherein the menopausal rat may be produced by ovariectomy...
|
|
|
US20120066779 |
HEPATITIS C RECEPTOR PROTEIN CD81
The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such...
|
|
|
US20110023144 |
GENOMIC EDITING OF GENES INVOLVED IN AMYOTROPHYIC LATERAL SCLEROSIS DISEASE
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated ALS. In particular, the animals or cells are...
|
|
|
US20110136100 |
NON-HUMAN ANIMAL DISEASE MODEL FOR HEPATITIS B VIRUS-ASSOCIATED DISEASE
A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and...
|
|
|
US20120030778 |
GENOMIC EDITING OF GENES INVOLVED WITH PARKINSONS DISEASE
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with Parkinson's disease. In particular, the animals or...
|
|
|
US20120094312 |
BOOSTING HUMAN DENDRITIC CELL DEVELOPMENT, HOMEOSTASIS AND FUNCTION IN XENOGRAFTED IMMUNODEFICIENT MICE
The present invention relates to a transgenic animal mode system based on the development of transgenic mice bearing components of the human immune system. Specifically, the Invention relates to a...
|
|
|
US20110052500 |
TAJ in Neuronal Function
The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by...
|
|
|
US20110003880 |
Compositions and methods for inhibiting optic nerve damage
Provided herein is a method of inhibiting optic nerve damage in an individual in need thereof, comprising administering to the individual an agent that inhibits peptidyl arginine deiminase 2...
|
|
|
US20110107442 |
Treatment of Male Sexual Dysfunction
A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a...
|
|
|
US20120066780 |
HUMANIZED NSG MOUSE, METHOD OF PRODUCING THE SAME AND USE THEREOF
A mouse model in which human fetal thymus and human fetal bone fragments are transplanted into NSG mice, a method of producing the same, and a use thereof.
|
|
|
US20110214191 |
METHOD FOR THE IDENTIFICATION OF GENES INVOLVED IN NEURODEGENERATIVE PROCESSES
A method for the identification of genes involved in neurodegenerative processes, detectable by the late onset of a phenotype associated with neurodegeneration, by means of a genetic screen of...
|
|
|
US20120022500 |
Compositions and Methods for Induced Brown Fat Differentiation
The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for p...
|
|
|
US20120110684 |
Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy
The present invention relates to a method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy.
|
|
|
US20110004947 |
COMPOSITIONS AND METHODS FOR OSTEOGENIC GENE THERAPY
The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids...
|
|
|
US20080209580 |
Mouse developing visceral fat type obesity and diabetes
An object of the present invention is to provide a mouse which has the characteristics of early developing visceral fat type obesity and also has concurrent diabetes and hyperlipemia and in which...
|
|
|
US20110110862 |
DISEASE ANIMAL MODEL FOR CHRONIC PAIN
A disease animal model, characterized in that a chronic pain is induced by applying a treatment for reducing the biogenic amine level to a mammal, and a method for screening for a therapeutic agent...
|
|
|
US20110321179 |
NON-HUMAN ANIMAL MODEL FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH LOSS-OF-TDP-43 FUNCTION
A non-human animal model for amyotrophic lateral sclerosis (ALS) is disclosed. The animal model comprises a rodent whose spinal cord motor neurons have a loss of TAR-DNA binding protein-43 (TDP-43)...
|
|
|
US20060130161 |
Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
Provided are non-human animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and autoimmune diseases such as diseases of the central nervous system, including...
|
|
|
US20120030779 |
COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS
Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or...
|
|
|
US20120117671 |
STEATOHEPATITIS-LIVER CANCER MODEL ANIMAL
Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result,...
|
|
|
US20110072524 |
Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand...
|
|
|
US20110219462 |
G-Protein Coupled Receptor 30 (GPR30) transgenic animals as a model for cardiovascular diseases
The present invention relates to use of the GPR30 gene for diagnosis and treatment of cardiovascular disorders, especially cardiomyopathy. The present invention also relates to a GPR30 deficient...
|
|
|
US20110138488 |
DEFICIENCY IN THE HISTONE DEMETHYLASE JHDM2A RESULTS IN IMPAIRED ENERGY EXPENDITURE AND OBESITY
The present invention relates to animal models of metabolic disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperinsulinemia, glucose intolerance, hyperlipidemia, and...
|
|
|
US20110067120 |
Iduronidase knock-out mouse
The present invention relates to a α-L-iduronidase knock-out mouse. More particularly, this invention relates to a α-L-iduronidase knock-out mouse to be designed for developing a treatment or an a...
|
|
|
US20110225661 |
METHOD FOR TREATING AND PREVENTING RADIATION DAMAGE USING GENETICALLY MODIFIED MESENCHYMAL STEM CELLS
A method of treating or preventing radiation damage by administering to a patient in need of treatment at least one therapeutically effective amount of a mesenchymal stem cell genetically altered...
|
|
|
US20100031379 |
NON-HUMAN ANIMAL FOR EYE DISEASE MODEL
It is intended to provide an animal model which shows a naturally occurring eye disease symptom, particularly ocular hypertension and/or retinal degeneration. The invention relates to a non-human...
|
|
|
US20110265194 |
THEM5-MODIFIED MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASE
The invention provides a new reproducible genetically-modified mouse model for the study of non-alcoholic fatty liver disease. In particular, the invention concerns the study of non-alcoholic fatty...
|
|
|
US20120060231 |
METHOD AND KIT FOR EVALUATION OF PREDISPOSITION TO DEVELOPMENT OF OBESITY, ANTI-OBESITY AGENT AND METHOD FOR SCREENING THEREOF, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, METHOD FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND ANTIBODY
It is an object of the present invention to provide a method of evaluating whether or not a subject has a predisposition to obesity or an obesity-related condition or disease, a kit for conducting...
|
|
|
US20110041193 |
NON-HUMAN MAMMAL MODEL OF EPILEPSY
The present invention provides a genuine epilepsy model animal as an improvement over conventional epilepsy model animals which are socalled seizures model animals mainly causing seizure attacks to...
|
|
|
US20070271620 |
Animal model for type II diabetes mellitus and Syndrome X and methods and uses thereof
The invention provides a method for generating a type II diabetes mellitus and/or Syndrome X model in pigs. A method of the invention comprises partially destructing pancreatic beta-cells in pigs....
|
|
|
US20110055939 |
METHOD FOR INTRODUCING FOREIGN GENE INTO EARLY EMBRYO OF PRIMATE ANIMAL AND METHOD FOR PRODUCING TRANSGENIC PRIMATE ANIMAL COMPRISING SUCH METHOD
An object of the present invention is to provide a method for introducing a gene into an embryo for production of a human disease model primate animal using a non-human primate animal such as a...
|
|
|
US20090070889 |
MOUSE MODEL COMPRISING AN ENGRAFTED HUMAN SKIN HAVING HYPERSENSITIVITY TO UV-LIGHT
The present invention relates to a humanized, non-human mammal model, preferably a humanized mouse model, with an engrafted portion of human skin having hyper-patient sensitivity to ultra violet...
|
|
|
US20120124682 |
DHX36 / RHAU KNOCKOUT MICE AS EXPERIMENTAL MODELS OF MUSCULAR DYSTROPHY
The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain a gene encoding an altered form of an DHX36 gene, the altered DHX36 haviang been targeted...
|
|
|
US20110236318 |
ANIMAL MODEL OF AN EJACULATION-LIKE REFLEX
An animal model of an ejaculation-like reflex, wherein the ejaculation-like reflex is induced by continuous infusion of saline through a catheter extending into the proximal urethra of a non-human...
|